VEGF-mediated STAT3 activation inhibits retinal vascularization by down-regulating local erythropoietin expression

American Journal of Pathology

Volumn 180, Issue 3, 2012, Pages 1243-1253

  Wang, Haibo ^a   Byfield, Grace ^b   Jiang, Yanchao ^a   Smith, George Wesley ^a   McCloskey, Manabu ^a   Hartnett, M Elizabeth ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; ERYTHROPOIETIN; GLUTAMATE AMMONIA LIGASE; OXYGEN; STAT3 PROTEIN; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HYPOXIA; MUELLER CELL; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; RETINA BLOOD VESSEL; RETINOPATHY; WESTERN BLOTTING;

ANIMALS; ANIMALS, NEWBORN; CASPASE 3; DOWN-REGULATION; ERYTHROPOIETIN; JANUS KINASES; OXYGEN; RATS; RATS, SPRAGUE-DAWLEY; RETINAL NEOVASCULARIZATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863174774     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2011.11.031     Document Type: Article

References (53)

1. J. Chen, L.E. Smith Retinopathy of prematurity Angiogenesis 10 2007 133 140
2. The Early Treatment for Retinopathy of Prematurity Cooperative Group The Early Treatment for Retinopathy Of Prematurity Study: structural findings at age 2 years Br J Ophthalmol 90 2006 1378 1382
3. D.B. Schaffer, E.A. Palmer, D.F. Plotsky, H.S. Metz, J.T. Flynn, B. Tung, R.J. Hardy Prognostic factors in the natural course of retinopathy of prematurity Ophthalmology 100 1993 230 237
4. L.P. Aiello Clinical implications of vascular growth factors in proliferative retinopathies Curr Opin Ophthalmol 8 1997 19 31
5. B. Nicholson, A. Schachat A review of clinical trials of anti-VEGF agents for diabetic retinopathy Graefes Arch Clin Exp Ophthalmol 248 2010 915 930
6. U.E. Wolf-Schnurrbusch, R. Ghanem, S.P. Rothenbuehler, V. Enzmann, C. Framme, S. Wolf Predictors of short-term visual outcome after anti-VEGF therapy of macular edema due to central retinal vein occlusion Invest Ophthalmol Vis Sci 52 2011 3334 3337
7. J. Chen, K.M. Connor, C.M. Aderman, L.E. Smith Erythropoietin deficiency decreases vascular stability in mice J Clin Invest 118 2008 526 533
8. C. Lofqvist, J. Chen, K.M. Connor, A.C. Smith, C.M. Aderman, N. Liu, J.E. Pintar, T. Ludwig, A. Hellstrom, L.E. Smith From the Cover: iGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth Proc Natl Acad Sci U S A 104 2007 10589 10594
9. A.R. O'Connor, T. Stephenson, A. Johnson, M.J. Tobin, M.J. Moseley, S. Ratib, Y. Ng, A.R. Fielder Long-term ophthalmic outcome of low birth weight children with and without retinopathy of prematurity Pediatrics 109 2002 12 18
10. K.H. Chang, T. Chan-Ling, E.L. McFarland, A. Afzal, H. Pan, L.C. Baxter, L.C. Shaw, S. Caballero, N. Sengupta, S.L. Calzi, S.M. Sullivan, M.B. Grant IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development Proc Natl Acad Sci U S A 104 2007 10595 10600
11. Y. Saito, P. Geisen, A. Uppal, M.E. Hartnett Inhibition of NAD(P)H oxidase reduces apoptosis and avascular retina in an animal model of retinopathy of prematurity Mol Vis 13 2007 840 853
12. M.R. Niesman, K.A. Johnson, J.S. Penn Therapeutic effect of liposomal superoxide dismutase in an animal model of retinopathy of prematurity Neurochem Res 22 1997 597 605
13. P. Geisen, L.J. Peterson, D. Martiniuk, A. Uppal, Y. Saito, M.E. Hartnett Neutralizing antibody to VEGF reduces intravitreous neovascularization and does not interfere with vascularization of avascular retina in an ROP model Mol Vis 14 2008 345 357
14. J.S. Penn, M.M. Henry, B.L. Tolman Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat Pediatr Res 36 1994 724 731
15. S. Cunningham, B.W. Fleck, R.A. Elton, N. Mclntosh Transcutaneous oxygen levels in retinopathy of prematurity Lancet 346 1995 1464 1465
16. M.E. Hartnett, D.J. Martiniuk, Y. Saito, P. Geisen, L.J. Peterson, J.R. McColm Triamcinolone reduces neovascularization. capillary density and IGF-1 receptor phosphorylation in a model of oxygen-induced retinopathy Invest Ophthalmol Vis Sci 47 2006 4975 4982
17. K. Liu, J.D. Akula, C. Falk, R.M. Hansen, A.B. Fulton The retinal vasculature and function of the neural retina in a rat model of retinopathy of prematurity Invest Ophthalmol Vis Sci 47 2006 2639 2647
18. J.S. Penn, B.L. Tolman, M.M. Henry Oxygen-induced retinopathy in the rat: relationship of retinal nonperfusion to subsequent neovascularization Invest Ophthalmol Vis Sci 35 1994 3429 3435
19. G.S. Robinson, L.P. Aiello Angiogenic factors in diabetic ocular disease: mechanisms of today, therapies for tomorrow Int Ophthalmol Clin 38 1998 89 102
20. A.P. Adamis, J.W. Miller, M.T. Bernal, D.J. DAmico, J. Folkman, T.K. Yeo, K.T. Yeo Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy Am J Ophthalmol 118 1994 445 450
21. S.J. Budd, H. Thompson, M.E. Hartnett Association of retinal vascular endothelial growth factor with avascular retina in a rat model of retinopathy of prematurity Arch Ophthalmol 128 2010 1014 1021
22. Y.H. Wang, M.L. Huang Organogenesis and tumorigenesis: insight from the JAK/STAT pathway in the Drosophila eye Dev Dyn 239 2010 2522 2533
23. Q. Xu, J. Briggs, S. Park, G. Niu, M. Kortylewski, S. Zhang, T. Gritsko, J. Turkson, H. Kay, G.L. Semenza, J.Q. Cheng, R. Jove, H. Yu Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways Oncogene 24 2005 5552 5560
24. G.E. Byfield, S. Budd, M.E. Hartnett Supplemental oxygen can cause intravitreous neovascularization through JAK/STAT pathways in a model of retinopathy of prematurity Invest Ophthalmol Vis Sci 50 2009 3360 3365
25. N. Meydan, T. Grunberger, H. Dadi, M. Shahar, E. Arpaia, Z. Lapidot, J.S. Leeder, M. Freedman, A. Cohen, A. Gazit, A. Levitzki, C.M. Roifman Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor Nature 379 1996 645 648
26. A.K. Banes, S. Shaw, J.A. Jenkins, H. Redd, F. Amiri, D.M. Pollock, M.B. Marrero Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli Am J Physiol Renal Physiol 286 2004 F653 F659
27. J.S. Penn, G.W. McCollum, J.M. Barnett, X.Q. Werdich, K.A. Koepke, V.S. Rajaratnam Angiostatic effect of penetrating ocular injury: role of pigment epithelium-derived factor Invest Ophthalmol Vis Sci 47 2006 405 414
28. T. Chan-Ling, B. Gock, J. Stone The effect of oxygen on vasoformative cell division: evidence that 'physiological hypoxia' is the stimulus for normal retinal vasculogenesis Invest Ophthalmol Vis Sci 36 1995 1201 1214
29. J. Stone, A. Itin, T. Alon, J. Peer, H. Gnessin, T. Chan-Ling, E. Keshet Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia J Neurosci 15 1995 4738 4747
30. A.L. Stewart, L. Rifkin, P.N. Amess, V. Kirkbride, J.P. Townsend, D.H. Miller, S.W. Lewis, D.P.E. Kingsley, I.F. Moseley, O. Foster, R.M. Murray Brain structure and neurocognitive and behavioural function in adolescents who were born very preterm Lancet 353 1999 1653 1657
31. M. Morita, O. Ohneda, T. Yamashita, S. Takahashi, N. Suzuki, O. Nakajima, S. Kawauchi, M. Ema, S. Shibahara, T. Udono, K. Tomita, M. Tamai, M. Yamamoto, Y. Fujii-Kuriyama HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin EMBO J 22 2003 1134 1146
32. K.K. Suk, J.A. Dunbar, A. Liu, N.S. Daher, C.K. Leng, J.K. Leng, P. Lim, S. Weller, E. Fayard Human recombinant erythropoietin and the incidence of retinopathy of prematurity: a multiple regression model J AAPOS 12 2008 233 238
33. J.E. Sears, G. Hoppe, Q. Ebrahem, B. Anand-Apte Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy Proc Natl Acad Sci U S A 105 2008 19898 19903
34. M.S. Brown, D. Eichorst, B. LaLa-Black, R. Gonzalez Higher cumulative doses of erythropoietin and developmental outcomes in preterm infants Pediatrics 124 2009 e681 e687
35. J.R. McColm, P. Geisen, M.E. Hartnett VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP Mol Vis 10 2004 512 520
36. Y. Saito, A. Uppal, G. Byfield, S. Budd, M.E. Hartnett Activated NAD(P)H oxidase from supplemental oxygen induces neovascularization independent of VEGF in retinopathy of prematurity model Invest Ophthalmol Vis Sci 49 2008 1591 1598
37. M.J. Bizzarro, N. Hussain, B. Jonsson, R. Feng, L.R. Ment, J.R. Gruen, H. Zhang, V. Bhandari Genetic susceptibility to retinopathy of prematurity Pediatrics 118 2006 1858 1863
38. R. Cervantes-Mungua, L. Espinosa-Lpez, P. Gmez-Contreras, G. Hernndez-Flores, J. Domnguez-Rodrguez, A. Bravo-Cullar Retinopathy of prematurity and oxidative stress ]in Spanish] An Pediatr (Barc) 64 2006 126 131
39. M. Al Shabrawey, M. Bartoli, A.B. El Remessy, D.H. Platt, S. Matragoon, M.A. Behzadian, R.W. Caldwell, R.B. Caldwell Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy Am J Path 167 2005 599 607
40. A. Patz, A. Eastham, D.H. Higginbotham, T. Kleh Oxygen studies in retrolental fibroplasia Am J Ophthalmol 36 1953 1511 1522
41. I.C. Michaelson The mode of development of the vascular system of the retina With some observations on its significance for certain retinal diseases Trans Ophthal Soc UK 68 1948 137 180
42. N. Ashton, B. Ward, G. Serpell Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia Br J Ophthalmol 38 1954 397 430
43. L.P. Aiello, E.A. Pierce, E.D. Foley, H. Takagi, H. Chen, L. Riddle, N. Ferrara, G.L. King, L.E. Smith Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins Proc Natl Acad Sci U S A 92 1995 10457 10461
44. M.E. Hartnett, D.J. Martiniuk, G.E. Byfield, P. Geisen, G. Zeng, V.L. Bautch Neutralizing VEGF decreases tortuosity and alters endothelial cell division orientation in arterioles and veins in rat model of ROP: relevance to plus disease Invest Ophthalmol Vis Sci 49 2008 3107 3114
45. M. Bartoli, D. Platt, T. Lemtalsi, X. Gu, S.E. Brooks, M.B. Marrero, R.B. Caldwell VEGF differentially activates STAT3 in microvascular endothelial cells FASEB J 17 2003 1562 1564
46. M.S. Brown, A.E. Baron, E.K. France, R.F. Hamman Association between higher cumulative doses of recombinant erythropoietin and risk for retinopathy of prematurity J AAPOS 10 2006 143 149
47. J. Chen, K.M. Connor, C.M. Aderman, K.L. Willett, O.P. Aspegren, L.E. Smith Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy Invest Ophthalmol Vis Sci 50 2009 1329 1335
48. Y. Yahata, Y. Shirakata, S. Tokumaru, K. Yamasaki, K. Sayama, Y. Hanakawa, M. Detmar, K. Hashimoto Nuclear translocation of phosphorylated STAT3 Is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation J Biol Chem 278 2003 40026 40031
49. M. Samardzija, A. Wenzel, S. Aufenberg, M. Thiersch, C. Reme, C. Grimm Differential role of Jak-STAT signaling in retinal degenerations FASEB J 20 2006 2411 2413
50. J.S. Rawlings, K.M. Rosler, D.A. Harrison The JAK/STAT signaling pathway J Cell Sci 117 2004 1281 1283
51. H.A. Mintz-Hittner, R.R. Kuffel Jr Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II Retina 28 2008 831 838
52. S. Budd, G. Byfield, D. Martiniuk, P. Geisen, M.E. Hartnett Reduction in endothelial tip cell filopodia corresponds to reduced intravitreous but not intraretinal vascularization in a model of ROP Exp Eye Res 89 2009 718 727
53. H. Sone, Y. Kawakami, A.K. Kumagai, Y. Okuda, Y. Sekine, S. Honmura, T. Segawa, H. Suzuki, K. Yamashita, N. Yamada Effects of intraocular or systemic administration of neutralizing antibody against vascular endothelial growth factor on the murine experimental model of retinopathy Life Sci 65 1999 2573 2580